Compare AURA & CHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURA | CHW |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 462.4M |
| IPO Year | 2021 | N/A |
| Metric | AURA | CHW |
|---|---|---|
| Price | $5.15 | $7.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $20.20 | N/A |
| AVG Volume (30 Days) | 184.4K | ★ 195.2K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.27% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $5.07 |
| 52 Week High | $8.60 | $6.54 |
| Indicator | AURA | CHW |
|---|---|---|
| Relative Strength Index (RSI) | 30.04 | 63.35 |
| Support Level | $5.30 | $7.40 |
| Resistance Level | $5.58 | $7.48 |
| Average True Range (ATR) | 0.36 | 0.09 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 7.19 | 94.68 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.